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A B S T R A C T
Mango consumption has shown bioactive properties against several diseases like diabetes, therefore, we eval-
uated how a mango-supplemented diet affects metabolic pathways in diabetic rats. Serum and liver samples were
collected from 26 rats divided into 3 groups (healthy, untreated diabetic and mango-treated diabetic) after
dietary intervention and analysed using an LC-MS untargeted metabolomic strategy. Twenty-six and 29 meta-
bolites in serum and liver were potentially annotated, showing significant differences among groups. Several
affected pathways were due to the disease state [fatty acids (i.e. palmitoleic, linolenic, stearidonic, eicosa-
pentaenoic, docosahexaenoic acids and others), bile acids (i.e. glycocholic acid) and amino acids (i.e. leucine,
isoleucine and valine)], and others due to mango supplementation (increased hepatic bioaccumulation of eu-
xanthone, a mangiferin metabolite, and increased glutathione concentration). These results suggest that a
mango-supplemented diet exerted a significant antioxidant effect in the liver of diabetic rats, likely due to its
phenolic compounds, like mangiferin and its metabolites.
1. Introduction
Diabetes mellitus (DM) is among the most prevalent chronic dis-
eases in the world, as stated by the International Diabetes Federation
(IDF). In 2017, there were approximately 451 million diagnosed pa-
tients and 5 million deaths worldwide were related to DM (Cho et al.,
2018). DM alludes to a group of metabolic disorders characterized by
chronic hyperglycemia, resulting from impaired insulin production by
pancreatic β-cells and/or insulin resistance by peripheral tissues (Goyal
& Jialal, 2018). Genetic, environmental and lifestyle (diet and exercise)
factors are among the different causes that can promote or prevent DM
development. Moreover, oxidative stress has been strongly associated
with DM pathogenesis and the progression of its comorbidities.
Recent studies have reported that vegetable byproducts, which are
often discarded in industrial processing (e.g. bark, peel, leaves, roots,
seeds, flowers, etc.), are potential sources of bioactive compounds that
can exert antidiabetic and antioxidant actions, similar to those of
commercially-available drugs (Naveen & Baskaran, 2018). Fenugreek,
avocado, garlic, pomegranate, grapes, guava and papaya are crops
whose bioactive components have been extensively studied as anti-
diabetics, mainly due to their powerful antioxidant activity and hy-
poglycemic effects, as proven in animal models and clinical trials
(Beidokhti & Jäger, 2017; Naveen & Baskaran, 2018). Among them,
mango (Mangifera indica L.) cv. ‘Ataulfo’ is an excellent source of nu-
tritional (vitamins, minerals, dietary fiber) and bioactive compounds
(carotenoids and phenolic compounds) with functional properties
(Palafox-Carlos, Yahia, & González-Aguilar, 2012).
Mango consumption, or that of its main bioactive compounds, has
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been linked to antimutagenic, anti-inflammatory, immunomodulatory,
antioxidant, hypoglycemic and antidiabetic effects (Martin & He, 2009;
Velderrain-Rodríguez et al., 2018). Previous studies have been carried
out to validate the effectiveness of consuming mango peel extract to
modulate oxidative stress and ameliorate various biochemical para-
meters in streptozotocin (STZ)-induced diabetic rats. Numerous me-
chanisms of action have been proposed to explain the effects observed,
for example, improving serum glucose uptake and catabolism, in-
creasing antioxidant system activity and inhibiting digestive starch-
hydrolyzing enzymes, among others (Gandhi et al., 2014; Gondi & Rao,
2015; Sellamuthu, Arulselvan, Muniappan, Fakurazi, & Kandasamy,
2013).
There is substantial evidence correlating diabetic complications to
disrupted common metabolic pathways. In this way, different meta-
bolites, such as some lipids, monosaccharides and amino acids have
been identified as altered in individuals with DM (Sas, Karnovsky,
Michailidis, & Pennathur, 2015). Having a thorough knowledge of how
these metabolites change in response to the disease and/or dietary
patterns, could be used as promising biomarkers that could lead to
improving early diagnosis, generate novel and effective treatments and
propose personalized dietary recommendations. These molecules have
been identified thanks to the recent development of metabolomic ap-
proaches, which aim to study a substantial number of low-molecular-
weight compounds present in biological systems (Agin et al., 2016).
Human clinical trials provide promising results but are not always
consistent, they have some limitations like elevated costs, duration of
the studies, sample size and high biological variability (Szkudelski &
Szkudelska, 2015). In the field of DM research, several animal models
have been developed to elucidate the mechanisms and metabolic al-
terations underlying DM and its comorbidities (King & Bowe, 2016).
STZ-induced diabetic rat models are widely used to evaluate metabolic
profiles (Chen et al., 2011), having some advantages such as standar-
dized protocols, quick onset of the disease, less expensive and faster
than others. In contrast, STZ-induced diabetes does not reflect the full
course of disease in humans, who usually develop after years of
asymptomatic metabolic alterations, beginning with insulin resistance,
progressing to impaired glucose metabolism and finally to DM. None-
theless, preclinical trials in animal models remain as the most viable
alternative for a better understanding of the disease and improving the
predictably of results in the discovery of new therapeutic agents for
human application.
Due to the promising beneficial effects of mango consumption in
DM, the aim of the present study was to evaluate metabolic changes in
serum and liver of STZ-induced diabetic Wistar rats, after prolonged
intake of bioactive compounds from ‘Ataulfo’ mango peel and pulp. Our
data will contribute to identifying potential changes to diabetes-related
biomarkers after consumption of a mango-supplemented diet rich in
bioactive compounds.
2. Material and methods
2.1. Animals and samples
All experiments involving living organisms were reviewed and ap-
proved by the Bioethics Committee of the Research Center for Food and
Development, where they were performed (CE/013/2018). Animals
were cared for and manipulated according to applicable local and in-
ternational rules and regulations, such as the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health and the
Mexican NOM-062-ZOO-1999. Twenty-six male Wistar rats
(280 ± 40 g initial weight) were obtained from the University of
Sonora, Mexico, and housed in individually ventilated metal cages
under standard conditions (12 h light/dark cycles at 24 ± 1 °C). After
seven days of acclimatization with free access to food and water, rats
were randomly divided into three groups: healthy control group (HC,
n = 7), untreated diabetic group (UD, n = 6) and mango-treated
diabetic group (MTD, n = 13). Diabetes was induced on UD and MTD
groups under overnight fasted conditions by an intraperitoneal dose of
STZ (60 mg/kg body weight) dissolved in 0.9% NaCl. Three days after
the STZ dose, blood samples were taken from the tail vein, and glucose
concentration was measured with a commercial glucose meter. Rats
with glycemia ≥200 mg/dL were considered diabetic and used for the
experiment. Initial and final glycemia and body weight gain were re-
gistered (Table S1).
HC and UD groups were fed a diet based on the standard A5001
diet; after diabetes was confirmed, the MTD group was immediately fed
with a diet supplemented with 5% and 10% lyophilized ‘Ataulfo’mango
peel and pulp, respectively. Diets were isoenergetic (3.5 kcal/g), with a
macro- and micronutrient content adequate for rodents (Table S2). The
phytochemical content of mango peel and pulp has been reported in
previous papers (see Supplemental Material) (Pacheco-Ordaz, Antunes-
Ricardo, Gutiérrez-Uribe, & González-Aguilar, 2018; Quirós-Sauceda
et al., 2017; Velderrain-Rodríguez et al., 2018).
The different diets were consumed by the animals for 5 weeks,
during which food and water were freely available and replenished
daily. After that period, they were fasted overnight (10 h), anesthetized
with a single intraperitoneal dose of sodium pentobarbital (120 mg/kg
body weight; Pisabental, PISA Agropecuaria, Atitalaquia, Hidalgo,
Mexico) and euthanized. Whole blood samples were collected in gold-
top serum separator Vacutainer tubes (Becton-Dickinson, Franklin
Lakes, NJ, USA) to obtain serum, while liver samples (0.5 g) were
lyophilized. Both types of samples were stored at −80 °C until pro-
cessed.
2.2. Sample treatment
Biological samples were thawed on ice before analysis. A quality
control sample (QC) was prepared for each matrix by combining equal
amounts of each case-study sample. This QC sample was treated like the
study samples as described below.
In the case of serum samples, a mixture of organic solvents (me-
thanol:ethanol, 50:50 v/v) was used for protein removal. The mixture
was kept for 30 min at −20 °C and then centrifuged (14,800 rpm, 4 °C,
10 min). The supernatant (200 µL) was evaporated to dryness. After
solvent evaporation, the dry residue was reconstituted in 100 µL of
H2O:methanol: (95:5, v/v) and centrifuged to collect an aliquot for
HPLC-MS analysis.
Regarding liver samples, 100 mg of lyophilized tissue were weighed
and mixed with 500 µL of methanol. Before LC-MS analysis, the me-
tabolites and proteins were extracted and removed, respectively. For
that, the mixture was vortex-mixed and then introduced into an ultra-
sonic bath for 3 min under refrigerated conditions. The mixture was
kept for 30 min at −20 °C and then centrifuged (14,800 rpm, 4 °C,
10 min). The supernatant was separated, and the extraction process was
repeated two more times using 250 µL of methanol:H2O (80:20, v/v).
The use of 100% or 80% methanol allows a better extraction of meta-
bolites and, therefore, thus a greater coverage of the metabolome (Wells
et al., 2018). The supernatants were mixed, and a 700 µL aliquot was
evaporated to dryness. Finally, the residue was reconstituted in 150 µL
of methanol:H2O (35:65, v/v), taking an aliquot for HPLC-MS.
2.3. HPLC-MS analysis.
Both biological samples were analyzed with the same HPLC-ESI-
QTOF-MS methodology. Metabolites were separated using an Agilent
Zorbax Eclipse Plus column (3.5 μm particle size, 150 mm × 2.1 mm).
The column was maintained at 25 °C in an Agilent 1260 HPLC instru-
ment. Mobile phases were water (A) and methanol (B), both containing
0.1% formic acid. These were used with a flow rate of 0.4 mL/min with
the following gradient: 0 min, 5% B; 5 min, 10% B; 15 min, 85% B;
32–40 min, 100% B; 45–50 min, 5% B. Injection volume was 5 µL, and
for avoiding possible degradation, samples were maintained at 4 °C in
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the auto-sampler compartment. The QC sample and an analytical blank
were repeatedly injected every five study samples throughout the
analytical sequence. Study samples were randomly injected into the
analytical sequence in order to avoid the risk of false positive and
carrier effects.
MS analyses were performed using an Agilent 6540 UHD Accurate
Mass Q-TOF analyzer. Data was acquired in negative-ion mode over a
50 to 1700 m/z range. For identification purposes, MS/MS analyses
were performed in QC samples with different collision energies (10, 20
and 40 eV). Ultrahigh purity nitrogen was used as drying (200 °C, 10 L/
min) and nebulizer gas (350 °C, 12 L/min). All masses were calibrated
by means of continuous infusion of the following substances: tri-
fluoroacetate anion (C2F3O2-, m/z 112.985587) and an adduct of HP-
921 (m/z 1033.988109). Both reference ions provided accurate mass
measurements, typically better than 2 ppm. The analytical metho-
dology is described in detail elsewhere (Fernández-Ochoa et al., 2019).
2.4. Data processing and statistical analysis
Batch Recursive Feature Extraction for small molecules was per-
formed using MassHunter Profinder software (B.06.00, Agilent
Technologies). Parameters for peak picking were an intensity threshold
of 1000 counts, an RT window of± 0.25 min, a mass window of
20 ppm ± 2 mDa and Agile2 as the integration method. Possible ad-
ducts with a maximum charge of 2 were the following: [M−H]-, [M
+Cl]-, [M−H2O-H]- and [M+HCOO]-.
Regarding statistical analyses, Principal Component Analysis (PCA)
was performed first to check the reproducibility and detect possible
outliers. In order to explore the metabolic differences in relation to the
different study groups, multivariate statistical test (Partial Least
Squares Discriminant Analysis (PLS-DA), and a hierarchical clustering
via heatmap) and univariate statistical tests (ANOVA) were performed.
Logarithmic transformation and Pareto scaling were applied to the data
before performing multivariate analyses. All statistical tests were car-
ried out in MetaboAnalyst 4.0 software (Chong et al., 2018). Molecular
features with VIP values higher than 1.50 in PLS-DA models were se-
lected for identification as potential biomarkers. Furthermore, analysis
of variance (ANOVA) was applied to these features, and those that were
not significant in this statistical test (p-value > 0.05) were discarded
for identification.
2.5. Metabolite identification
Identification of the selected molecular features in statistical tests
was carried out by comparing accurate mass, isotopic distribution and
fragmentation patterns obtained in MS/MS analysis with available on-
line metabolomic databases. Databases were searched by CEU Mass
Mediator tool (Gil de la Fuente, Grace Armitage, Otero, Barbas, &
Godzien, 2017). This tool allowed simultaneous metabolite search in
several databases such as METLIN, LipidMaps, KEGG as well as Human
Metabolome Database. The MS/MS patterns were also compared with in
silico MS/MS fragmentation resources, concretely, MetFrag (https://
ipb-halle.github.io/MetFrag/).
3. Results
3.1. Data quality assessment
After data pre-processing, 770 and 508 molecular features were
extracted from liver and serum samples, respectively. After that, 19 and
32 features were discarded from both datasets, respectively, due to a
Relative Standard Deviation (RSD) in QC samples higher than 30%.
PCA was performed to detect outliers and check analytical reproduci-
bility (Ulaszewska et al., 2019). In this sense, a well grouping of the QC
samples in the PCA scores plot (see Fig. S1, supplemental material)
indicated a good reproducibility of the obtained data. However, the first
main component (PC1) of both models explained great differences be-
tween specific samples (one serum and three liver samples) and the rest
of the samples. This fact implied that the separated samples were as-
signed as outliers, and, therefore, were discarded for the rest of the
statistical analyses. Despite this, differences between groups (HC, UD
and MTD) were detected thanks to the information explained by the
second component (PC2) in both PCA analyses. These groupings were
more clearly observed in the PCA of the liver samples. Therefore, PCA
analyses were performed again without the outliers and QC samples
(Fig. 1). As mentioned above, higher differences among HC, UD and
MTD groups were observed in the case of liver samples. The variability
explained by PC1 (46.2%) showed a clear separation among all groups
Fig. 1. PCA scores plots from data obtained in the analyses from liver (a) and serum samples (b) after the removal of outliers and QC samples. (Red dots, healthy
controls, HC; green dots, untreated diabetic group, UD; blue dots, mango-treated diabetic group, MTD). (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)
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(Fig. 1a). Regarding serum samples, no clear separations among the
three groups were observed, as in the case of liver samples, however, a
clear separation between diabetic and healthy rats was detected, as well
as a good grouping of the HC samples (Fig. 1b).
3.2. PLS-DA models and analysis of variance (ANOVA)
PLS-DA models were built to discriminate samples according to
different classes (HC, UD and MTD). Fig. 2 shows the main results of
both models. Analogous to PCA results, the three classes were better
separated by the PLS-DA model created with liver data. Clearly, all
three classes were separated by PC1 (38.9%) in the PLS-DA model. On
the other hand, PC1 (25%) in the model created with serum data se-
parated the healthy controls and diabetic samples. In addition, PC2
(18.1%) differentiated rats from the UD group, to those that consumed
mango-supplemented diets (MTD).
For model assessment, accuracy, R2 and Q2 values were obtained by
10-fold cross validation (CV) method for the PLS-DA models with two
components. Analogous to the sample distribution observed in score
plots, better results were obtained with the model created with liver
data (Accuracy: 0.95, R2: 0.98 and Q2: 0.95), as compared to the model
with serum data (Accuracy: 0.92, R2: 0.84 and Q2: 0.64). Permutation
tests were also performed, in which p-values lower than 0.01 were
obtained from both models (Fig. 2c, d), indicating a lack of overfitting
in these models. After PLS-DA and ANOVA, 51 and 39 molecular fea-
tures from liver and serum, respectively, were selected for identifica-
tion. Then, 26 and 29 metabolites for serum and liver, respectively,
could be annotated (Tables 1 and 2). According to the Metabolomics
Standards Initiative (MSI), proposed metabolites were putatively
annotated (Sumner et al., 2007) using the MS/MS fragments (Tables
S3–S4). Regarding unknown features, Tables S5–S6 show their corre-
sponding parameters.
3.3. Hierarchical clustering analysis via heatmap
Hierarchical clustering analyses via heatmap were performed to the
annotated metabolites using a Pearson distance measure and Ward
clustering algorithm. Fig. 3 shows results obtained for these analyses. In
both models, sample clustering shows three clear clusters (S1, S2 and
S3), related to the three classes of samples (MTD, HC and UD), re-
spectively. Regarding variable clustering, different clusters were clearly
established. In liver model, four clusters (L1, L2, L3 and L4) were as-
signed (Fig. 3a). L1 and L2 clusters were clearly influenced by the
mango-supplemented diet, while L3 and L4 seemed to be more related
to diabetes. Regarding serum clustering (Fig. 3b), three clusters were
established (P1, P2 and P3). The first two were made up of altered by
diet, while the third cluster corresponded to metabolites influenced by
diabetes.
4. Discussion
A detailed understanding of the pathophysiology of DM by identi-
fying its metabolic alterations is imperative for early diagnosis and the
development of possible preventive strategies and effective treatments.
In the present study, we attempted to inspect the metabolic profile of
serum and liver of STZ-induced diabetic rats using HPLC-ESI-QTOF-MS,
and explore the alterations generated by a mango-supplemented diet.
The most affected pathways by the pathology were related to fatty acid
Fig. 2. A Supervised Partial Least Squares Discriminant Analyses (PLS-DA). (a, b): PLS-DA score plot (a: liver model; b: serum model). (Red dots, healthy controls, HC;
green dots, untreated diabetic group, UD; blue dots, mango-treated diabetic group, MTD). Permutation test results using separation distance (B/W) (c: liver model, d:
serum model). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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metabolism, bile acid homeostasis and amino acid catabolism, while
metabolites enhanced by the mango treatment were associated with the
antioxidant system. The following section discusses what metabolomic
changes were documented, as well as their implications; they were
grouped according to changes that were due to mango supplementation
(4.1) and those of the disease itself (4.2).
4.1. Metabolic changes related to molecular mechanisms in response to
mango-supplemented diet
The effects of mango peel and pulp intake on the serum and liver
metabolome in STZ-induced rats were studied. The major findings as-
sociated with diet consumption were the presence of euxanthone and
glutathione, molecules that are related to the enhancement of the an-
tioxidant status of the liver of diabetic rats, among other biological
properties, which are discussed in further detail below.
Table 1
Retention times, masses, VIP, FDR and the results of the Tukey’s HSD from annotated metabolites present in serum samples.
RT (min) Mass (Da) VIP value FDR Tukey’s HSD Molecular Formula Score (%) Metabolite
22.58 302.2258 3.86 2.85E−08 T-C; T-D C20H30O2 97.82 Eicosapentanoic acid (EPA)
19.19 318.2227 3.56 2.57E−08 T-C; T-D C20H30O3 95.54 12-HEPE
17.95 465.3130 3.16 5.76E−03 D-C; T-C C26H43NO6 97.27 Glycocholic acid
1.5 270.0931 2.93 9.12E−07 D-C; T-C C10H14N4O5 87.3 Histidinyl-Aspartate (His-Asp)
17.71 408.294 2.62 3.19E−02 T-C C24H40O5 76.36 Cholic acid
1.42 279.1320 2.56 2.69E−03 D-C; T-C C11H21NO7 58.12 N-(1-Deoxy-1-fructosyl)valine
24.58 330.2550 2.55 3.77E−07 T-C; T-D C22H34O2 97.93 Docosapentaenoic acid (DPA)
12.71 284.0918 2.55 2.52E−02 T-C C13H16O7 91.16 p-Cresol glucuronide
23.71 678.4681 2.28 1.80E−05 D-C; T-C; T-D C39H67O7P 87.31 PA(P-36:5)
12.01 86.0735 2.13 3.86E−04 D-C; T-C C5H10O 85.06 Iso-valeraldehyde
6.79 118.1311 2.05 6.05E−04 D-C; T-C C5H10O3 84.99 3-hydroxyisovaleric acid
23.13 254.2265 2.05 4.81E−03 D-C; T-C C16H30O2 98.52 Palmitoleic acid
23.14 276.4137 2.02 3.93E−03 D-C; T-C C18H28O2 80.27 Stearidonic acid
34.7 583.5189 1.94 1.65E−04 D-C; T-C C34H67NO3 78.75 Cer(d18:1/16:0)
11.37 122.0373 1.91 5.77E−03 D-C; T-C C7H6O2 98.88 4-Hydroxybenzaldehyde
25.99 332.2735 1.87 8.95E−04 T-C; T-D C22H36O2 72.81 Adrenic Acid
1.51 129.0406 1.87 3.00E−03 T-C; T-D C5H7NO3 87.4 Pyroglutamic acid
23.7 396.2277 1.84 1.13E−06 T-C; T-D C18H37O7P 94.52 PA(15:0)
1.76 129.0419 1.83 4.66E−04 D-C; T-C C5H7NO3 93.43 Pyrrolidonecarboxylic acid
23.71 396.2320 1.77 1.13E−06 D-C; T-C; T-D C18H37O7P 99.21 (9S,10S)-10-hydroxy-9-(phosphonooxy)octadecanoate
23.72 328.2431 1.77 3.13E−06 D-C; T-C; T-D C22H32O2 96.02 Docosahexaenoic acid (DHA)
22.7 300.4351 1.71 2.14E−02 T-C C20H28O2 65.90 Retinoic acid
12.79 173.1054 1.65 4.07E−02 T-C C8H15NO3 84.38 Hexanoylglycine
22.71 278.2261 1.57 2.56E−02 T-C C18H30O2 76.03 Linolenic acid
21.17 567.3359 1.54 4.81E−03 D-C; T-C C30H50NO7P 92.64 LysoPC(22:6)
23.78 654.4694 1.53 1.11E−04 T-C; T-D C44H62O4 72.04 14-DHAHDHA
Table 2
Retention times, masses, VIP, FDR and the results of the Tukey’s HSD from annotated metabolites present in liver samples.
RT (min) Mass (Da) VIP value FDR Tukey’s HSD Molecular Formula Score (%) Metabolite
7.61 358.1014 3.54 1.04E−10 T-C, T-D C11H23N2O7PS 91.76 Pantetheine 4′’-phosphate
17.34 228.0429 3.53 5.00E−17 T-C, T-D C13H8O4 95.11 Euxanthone
34.15 825.5523 3.38 6.74E−25 T-C, T-D C45H80NO10P 96.77 PS(39:4)
15.79 320.1476 3.35 3.26E−07 D-C, T-C C14H28O8 97.85 Octanoylglucoronide
1.47 345.0379 3.24 2.23E−16 T-C, T-D C10H12N5O7P 53.27 Cyclic GMP
1.47 307.0847 3.21 1.56E−06 T-C, T-D C10H17N3O6S 92.63 Glutathione
3.05 216.1133 1.68 3.04E−07 D-C, T-C, T-D C9H16N2O4 86.73 Pro-Thr
7.25 282.1076 1.64 1.58E−09 D-C, T-C, T-D C10H14N6O4 88.44 2-Aminoadenosine
2.75 176.0691 1.59 1.88E−06 D-C, T-C, T-D C7H12O5 78.56 2-Isopropylmalic acid
27.94 676.5406 1.57 7.57E−07 D-C, T-C, T-D C38H77O7P 97.54 PA(O-18:0/17:0)
1.41 347.0596 1.57 3.45E−08 D-C, T-C, T-D C10H14N5O7P 99.15 Adenosine monophosphate
3.28 267.0994 1.55 1.27E−06 D-C, T-C, T-D C10H13N5O4 66.33 Adenosine
7.25 89.0468 1.54 1.27E−06 D-C, T-C, T-D C3H7NO2 94.58 beta-Alanine
25.08 330.255 1.54 1.51E−06 D-C, T-C, T-D C22H34O2 76.84 Docosapentaenoic acid (DPA)
12.79 173.1059 1.54 2.58E−06 D-C, T-C, T-D C8H15NO3 86.99 N-Acetylisoleucine
14.39 172.1103 1.54 1.27E−06 D-C, T-C, T-D C9H16O3 99.9 9-oxo-nonanoic acid
5.43 327.1332 1.53 2.58E−06 D-C, T-C, T-D C15H21NO7 97.34 N-(1-Deoxy-1-fructosyl)phenylalanine
2.23 343.1256 1.53 1.90E−06 D-C, T-C, T-D C15H21NO8 70.01 N-(1-Deoxy-1-fructosyl)tyrosine
2.38 181.0721 1.53 2.84E−06 D-C, T-C, T-D C9H11NO3 70.05 L-Tyrosine
2.64 293.1509 1.52 2.08E−06 D-C, T-C, T-D C12H23NO7 70.28 N-(1-Deoxy-1-fructosyl)leucine/N-(1-Deoxy-1-fructosyl)isoleucine
1.53 541.0576 1.52 6.47E−09 T-C, T-D C15H21N5O13P2 91.89 Cyclic ADP-ribose
22.67 521.3481 1.51 7.83E−07 T-C, T-D C26H52NO7P 89.79 LysoPC(18:1)
5.42 237.1027 1.51 5.48E−06 D-C, T-C, T-D C12H15NO4 97.49 N-lactoyl-phenylalanine
2.64 203.1178 1.41 2.08E−06 T-C, T-D C9H17NO4 91.58 N-lactoyl-Leucine
2.39 131.095 1.50 5.78E−06 D-C, T-C, T-D C6H13NO2 76.63 Beta-Leucine
9.72 366.1447 1.50 7.72E−06 D-C, T-C, T-D C17H22N2O7 84.06 N-(1-Deoxy-1-fructosyl)tryptophan
22.67 507.3321 1.50 9.84E−07 T-C, T-D C25H50NO7P 94.44 LysoPE(20:1)
6.41 284.0768 1.50 5.87E−06 D-C, T-C, T-D C10H12N4O6 89.96 Xanthosine
7.25 219.1161 1.50 7.49E−06 D-C, T-C, T-D C9H17NO5 82.88 Pantothenic acid
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4.1.1. Euxanthone
Euxanthone was only detected and positively identified in the
mango-treated group (L2). Mango contains numerous bioactive; how-
ever, the only metabolite that bioaccumulated/biotransformed in the
liver was euxanthone. This substance is a metabolite from mangiferin, a
bioactive compound found in mango and mangosteen (Garcinia man-
gostana Linn.) (Pedraza-Chaverri, Cárdenas-Rodríguez, Orozco-Ibarra,
& Pérez-Rojas, 2008). When mangiferin is orally consumed, intestinal
bacteria first deglycosylate it to norathyriol, leaving the core phenolic
scaffolding intact (Sanugul et al., 2005). Norathyriol is then further
metabolized into euxanthone by removing two hydroxyl groups at po-
sitions 3 and 6 (Derese, Guantai, Yaouba, & Kuete, 2017). Mangiferin
and its metabolites are of high interest due to numerous health-pro-
moting effects documented, such as antioxidant, anti-inflammatory,
antidiabetic and others (Martin & He, 2009).
It has been shown that mangiferin is able to modulate different
signaling molecules, including mitogen-activated protein kinases
(MAPKs), nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) and protein kinase C (PKC) isoforms (Saha, Sadhukhan, & Sil,
2016), the latter related to the non-enzymatic formation of advanced
glycation end products (AGEs) in hyperglycemic organisms (Das
Evcimen & King, 2007). Additionally, mangiferin suppresses some pro-
inflammatory cytokines (Saha et al., 2016) and inhibits enzymes asso-
ciated with carbohydrate metabolism, such as α-amylase and α-gluco-
sidase (Sekar, Chakraborty, Mani, Sali, & Vasanthi, 2019), thereby ex-
erting beneficial effects in STZ-induced diabetic rats (Gondi & Rao,
2015).
Our results suggest that euxanthone is bioaccumulated in the liver
of diabetic rats after consuming a diet rich in ‘Ataulfo’ mango peel and
pulp for five weeks, possibly contributing to the antidiabetic effects of
this diet.
4.1.2. Glutathione
Glutathione was found at higher concentration in the liver of MTD
rats, as compared to HC and UD animals. This finding suggests that
mango consumption exerted a profound antioxidant effect by stimu-
lating the endogenous antioxidant system. Oxidative stress in diabetic
organisms is well documented and correlates strongly with diabetic
complications in most affected organs (Tangvarasittichai, 2015). Var-
ious authors have found a protective effect of phenolic-rich foods or
extracts. For example, Arafat et al., (Arafat et al., 2016) administered
Momordica charantia fruit pulp to alloxan-induced diabetic rats, and
found a restored hepatic glutathione concentration. Abdel-Moneim,
Yousef, Abd El-Twab, Abdel Reheim, & Ashour (2017) report that gallic
acid and p-coumaric acid (both present in mango pulp) prevent brain
glutathione depletion in STZ-induced diabetic rats. Finally, it has been
shown that a mangiferin pretreatment increases glutathione levels and
enhances the activity of glutathione-related enzymes in cardiac tissue of
rats (Prabhu, Jainu, Sabitha, & Devi, 2006), which could be related to
the findings of the present work. Therefore, our data suggests that
mango supplementation apparently prevents glutathione depletion in
livers of diabetic rats. This is likely due to the many phenolic com-
pounds present in ‘Ataulfo’ mango peel (mangiferin) and pulp (gallic
acid, chlorogenic acid, protocatechuic acid and vanillic acid), which
countered some of the pro-oxidative effects of diabetes.
4.2. Metabolic changes related to molecular pathophysiological mechanisms
of diabetes
In addition to increased hyperglycemia, the UD group had a sig-
nificantly lower weight gain than the HC and MTD groups. Induction
with STZ caused a perceptible weight loss from the first week explained
by the depletion of muscle and adipose tissue. However, the con-
sumption of mango-supplemented diet resulted in substantial im-
provement in weight gain and the maintenance of glucose during the
trial (Table S1). Particularly, changes in serum and liver metabolites
were mainly related to alterations of fatty acids, bile acids, amino acids,
pantothenate, and nucleotide metabolism. The above-mentioned
changes are consistent with some known disrupted mechanisms linked
to DM and its complications in STZ-induced rat models.
4.2.1. Fatty acid metabolism
Most changes documented in serum were related to fatty acids, their
metabolites and phospholipids, indicating that lipid metabolism was
Fig. 3. Hierarchical clustering via heatmap using Pearson as distance measure and Ward as clustering algorithm, of the significant annotated metabolites. (a: liver
model; b: serum model).
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significantly altered. Interestingly, changes were found on mono-
unsaturated fatty acids (MUFAs) and polyunsaturated fatty acids
(PUFAs).
Palmitoleic acid decreased in both diabetic groups, as compared to
the control. This MUFA is a lipokine that can promote peripheral insulin
sensitivity in muscle cells via p-38 MAPK signaling (Talbot, Wheeler-
Jones, & Cleasby, 2014), and in animal models by up-regulating the
expression of carbohydrate- and lipid-catabolizing genes (Duckett,
Volpi-Lagreca, Alende, & Long, 2014). Furthermore, linolenic acid and
stearidonic acid were also significantly altered, with a decreasing ten-
dency in both diabetic groups, while the concentration of eicosa-
pentaenoic acid (EPA) was lower in the MTD group. These ω-3 fatty
acids have shown bioactivities related to insulin resistance, and their
consumption has been explored and suggested to be useful in type 2
diabetes (Jovanovski, Li, Thanh Ho, Djedovic, & Marques, 2017).
Adrenic acid, docosapentaenoic acid (DPA), docosahexaenoic acid
(DHA) and 14-(docosahexaenoyloxy) docosahexaenoic acid (14-
DHADHA) also showed significant changes. Increased levels of adrenic
acid have been correlated with decreased insulin sensitivity and with
increased area under the glucose curve in a type 2 diabetic male po-
pulation (Lankinen et al., 2015). The effects of DHA have been shown to
oppose those of previously-mentioned ω-6 fatty acids, for example,
dietary supplementation with ω-3 fatty acids (including DHA) can im-
prove some endocrine and anthropometric parameters in a type-2 dia-
betic population (Jacobo-Cejudo et al., 2017). In addition, branched
fatty acid esters of hydroxy fatty acids (FAHFAs) such as 14-DHADHA
has been reported to exert anti-inflammatory and anti-diabetic prop-
erties, mainly in type 2 diabetes in humans and rats (Balas, Durand, &
Feillet-Coudray, 2018).
Taken together, these results showed an increased level of pro-in-
flammatory ω-6, concurrent with a decreased level of anti-in-
flammatory ω-3 fatty acids. An increased ω-6-to-ω-3 ratio has been
correlated with cardiac events (Takahashi et al., 2017), suggesting that
dietary supplementation of ω-3 could be beneficial in diabetic organ-
isms.
In addition to free fatty acids, phospholipids [PA(P-36:5), PA(15:0/
0:0), LPC(22:6)] and sphingolipids [ceramide (d18:1/16:0)] were also
significantly altered in serum of diabetic rats. The behavior of these
compounds (Fig. 3) suggests that phospholipase activity increased in
the absence of insulin (Lin et al., 2016). This fact has also been found to
be related to oxidative stress (Yui et al., 2015). Both phospholipids and
sphingolipids are key metabolic mediators that modulate intracellular
signaling related to insulin, as well as numerous other processes, which
makes them important targets to prevent, mitigate or revert metabolic
anomalies (Meikle & Summers, 2017).
4.2.2. Bile acids
Significant changes were documented on the serum concentration of
cholic acid and glycocholic acid. The upregulation of glycocholic acid
has been considered a circulating metabolomic biomarker of the dis-
ease. The regulation of hepatic bile acid metabolism has been linked to
a possible prevention of insulin resistance, as observed in previous
studies. In fact, a role as a ligand of the farnesoid X receptor (FXR), also
known as bile acid receptor, has been assigned to bile acids (Cipriani,
Mencarelli, Palladino, & Fiorucci, 2010; Renga, Mencarelli, Vavassori,
Brancaleone, & Fiorucci, 2010). FXR is a transcription factor that,
among other functions, stimulates insulin transcription and secretion
from pancreatic β-cells.
4.2.3. Branched-chain amino acids (BCAAs) and aromatic amino acids
metabolism
Main changes in liver amino acids were related to branched and
aromatic amino acids. BCAAs and some of their derivatives like leucine,
N-(1-deoxy-1-fructosyl)-leucine, N-lactoyl-leucine and N-(1-deoxy-1-
fructosyl)-isoleucine were all increased in the liver of diabetic groups
(UD and MTD), whereas, N-(1-deoxy-1-fructosyl)-valine was increased
in serum, demonstrating an impaired amino acid metabolic control, as
revealed in one-week STZ-induced diabetic rats (Diao et al., 2014).
It is well known that STZ-diabetic induced rats are susceptible to
increased protein catabolism in tissues like skeletal muscle, which leads
to an alteration in diverse amino acid metabolic pathways, increasing
circulating BCAA levels (Rodríguez et al., 1997). Since the liver is one
of the principal tissues where BCAA oxidation takes place (60–83%), it
is possible that excess of α-ketoacids produced from BCAA in muscles
by proteolysis in diabetic organisms, is metabolized here and modu-
lated by the branched-chain α-keto acid dehydrogenase complex
(BCKDH) in this organ. This BCKDH complex would lead to the for-
mation of acetyl-CoA or succinyl-CoA, which can enter the tricarboxylic
acid cycle (TCA); once there, they can be converted into pyruvate or
any gluconeogenic TCA intermediate (Neinast et al., 2019). However,
hepatic BCKDH activity has been shown to decrease in diabetic rat
models (Doisaki et al., 2010; Kuzuya et al., 2008), which could increase
hepatic BCAA concentration. We also found a significant increase in
alanine levels (tentatively produced by BCAA transamination with
pyruvate), which is related to the glucose-alanine cycle from muscle to
the liver, which apparently supplies gluconeogenic substrates due to a
lack of inhibitory insulin signaling (Suhre et al., 2010).
Finally, our results show the upregulation of three aromatic amino
acids or its fructosyl derivatives (phenylalanine, tyrosine, and trypto-
phan) in both diabetic groups (UD and MTD), which is consistent with
data reported by Lanza et al. (Lanza et al., 2010). Changes in aromatic
amino acids have been associated with perturbations in gut microbiota
(Neis, Dejong, & Rensen, 2015), which has been reported as altered in
patients with impaired glucose metabolism (Chen et al., 2016). In
diabetic organisms, AGEs are formed when reducing sugars (such as
glucose and fructose) spontaneously react with proteins, which has
been linked to the development of diabetic neuropathy, nephropathy
and retinopathy, among other complications (Karachalias, Babaei-
Jadidi, Ahmed, & Thornalley, 2003).
As the concentration of fructose in serum is much lower than that of
glucose, this molecule has not been a central focus on glycation re-
search. However, it is more reactive than glucose, and has been re-
ported to be elevated via polyol pathway activation in diabetic tissues
(Gallagher, LeRoith, Stasinopoulos, Zelenko, & Shiloach, 2016).
Non-enzymatic reactions between reducing sugars and amines de-
pend on their circulating levels, promoting the spontaneous formation
of early glycation products (EGPs), including N-terminal fructosyl
compounds, which are precursors of AGEs (Beisswenger, 2012). As seen
in cluster L3 of the heatmap, our results show that all BCAAs and
aromatic amino acids in liver and serum of diabetic rats (UD and MTD)
were glycated with fructosamine residues (L3). The AGE levels and N-
fructosyl-lysine were described to be increased in retinal, renal glo-
meruli, sciatic nerve and serum proteins in STZ-induced diabetic rats,
which was related to high glycemia (Karachalias, Babaei-Jadidi,
Rabbani, & Thornalley, 2010). In a previous study, increased glycated
hemoglobin (HbA1 = 17.7 ± 1.6%) was associated with the presence
of N-fructosyl-valine in diabetic rats after a 24-week period
(Karachalias et al., 2003). We can argue that in organisms with altered
glucose homeostasis, glycation reactions of amino acids and other
molecules increase, causing protein dysfunction and disruption of
amino acid metabolism.
4.2.4. Pantothenate and CoA biosynthesis
According to our results, different precursors of CoA showed
changes between groups. Pantothenic acid levels were higher in the
liver of both diabetic groups, as compared to the control (L4), while
pantetheine 4′’-phosphate was upregulated in the MTD group (L2),
suggesting an increased synthesis of CoA with predicted impact on
acetyl-CoA production. An increased generation of acetyl-CoA is linked
to excessive fatty acid oxidation in the liver of fasted and diabetic rats
(due to the lack of carbohydrate utilization), which are metabolized in
TCA or HMG-CoA pathways to produce ATP or ketone bodies,
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respectively (McGarry & Foster, 1980; Wieland, Weiss, & Eger-Neufeldt,
1964).
4.2.5. Nucleotide metabolism
This study showed a decreased in adenine and AMP concentrations
in the liver of both diabetic groups (UD and MTD), while there was an
increase of 2-aminoadenosine and xanthosine in the liver of both dia-
betic groups, as compared to the HC (L1, and L4, respectively).
Meanwhile, cGMP was upregulated in the MTD group (L2).
Nucleotides play a pivotal role in most metabolic pathways, acting
as part of nucleic acids, coenzymes and signaling molecules. It has been
reported that adenosine, AMP, guanosine, GMP, GTP, inosine and IMP
are increased in type 1 and type 2 diabetes (Dudzinska, 2014; Huang
et al., 2011). Increased nucleoside levels could be a result of an ac-
celerated nucleotide degradation under diabetic conditions, changes in
the enzymes and transporters responsible for their metabolism, and
alterations at the genetic level (Dudzinska, 2014). Xanthosine elevation
could suggest an accelerated breakdown of the xanthine in purine
metabolism, which is associated with oxidative stress in the liver of
diabetic rats (Kristal, Vigneau-Callahan, Moskowitz, & Matson, 1999).
Regarding the increased cGMP in MTD group, the effect of phenolic
compounds on the prevention and treatment of cardiovascular diseases
and hypertension has been described, which are linked to stimulating
endothelial nitric oxide (NO) and vasorelaxation via cGMP pathway
(Benito et al., 2002). cGMP is a second messenger that promotes glu-
cose-stimulated insulin secretion, prevents β-cells apoptosis and pro-
mote its differentiation, however, modulation of guanosine metabolites
remains unclear in diabetic organisms.
5. Conclusions
The present study identified potential biomarkers related to diabetic
disorders involving significant changes to fatty acid, amino acid, bile
acid, pantothenate and nucleotide pathways. Furthermore, the meta-
bolomic approach used found two main hepatic metabolites (eu-
xanthone and glutathione) linked to mango-based dietary intervention,
suggesting that some bioactive compounds present therein are bioa-
vailable and can reach target tissues such as the liver. These findings
also demonstrated that ‘Ataulfo’ mango consumption improves the
antioxidant status of diabetic rats. Results may contribute to a better
understanding of the metabolic changes that take place in diabetic or-
ganisms, and the effects of bioactive compounds from mango in STZ-
induced diabetic rats. Nonetheless, further research is still needed in
order to verify or refute the associations of the possible bioactivity of
phenolic compounds in other altered animal tissues or in a nutritional
intervention in humans.
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